Citi lowered the firm’s price target on Bristol Myers (BMY) to $47 from $51 and keeps a Neutral rating on the shares. The company reported solid Q2 results but faces increased spending in future years due to pipeline catalyst prioritization, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Sell Rating for Bristol-Myers Squibb Due to Overly Optimistic Estimates and Clinical Trial Delays
- Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges
- Bristol-Myers Squibb Reports Strong Q2 2025 Results
- BMY Earnings: Bristol Myers Squibb Stock Rises on Q2 Beats & Strong 2025 Guidance
- Trump posts letters calling on drug company CEOs to lower prices